Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Integrating dynamic analysis of serial ctDNA testing to enhance diagnostic and prognostic assessments in patients with metastatic breast cancer.

Qiang Zhang, Andrew A. Davis, Justin Weicheng Zhang et al. Jun 01, 2025 pp. 1042-1042 10.1200/jco.2025.43.16_suppl.1042

1042 Background: The monitoring of circulating tumor DNA (ctDNA) in patient with metastatic breast cancer (MBC) plays a critical role in predicting therap...

Sociodemographic differences in lung cancer mortality trends across the United States (US) rural-urban divide.

Dena Rhinehart, Amanda L. Blackford, Aakash Desai et al. Jun 01, 2025 pp. 11048-11048 10.1200/jco.2025.43.16_suppl.11048

11048 Background: It is known that rural populations face higher lung cancer mortality than urban populations, but it is u...

Circulating tumor DNA (ctDNA) analysis for improved treatment response assessment and prediction of clinical outcomes in patients with esophageal cancer.

Zexi Allan, Hillary S. Sloane, Kneshay Harper et al. Jun 01, 2025 pp. 4077-4077 10.1200/jco.2025.43.16_suppl.4077

4077 Background: Despite curative-intent treatment, patients with esophageal cancer experience a high risk of recurrence, and optimal patient management i...

A generative model for the design of novel inhibitors targeting the PD-1/PD-L1 pathway.

Juan Velasco Jun 01, 2025 pp. 2576-2576 10.1200/jco.2025.43.16_suppl.2576

2576 Background: The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) signaling pathway plays a pivotal role in tumor immunosuppression...

Comprehensive molecular analysis of phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma.

Hyo Song Kim, Kum-Hee Yun, Nam Suk Sim et al. Jun 01, 2025 pp. 11555-11555 10.1200/jco.2025.43.16_suppl.11555

11555 Background: We conducted an open-label, phase IB/II study to determine the activity and safety of the standard-of-care, doxorubicin in combined with...

Outcomes with CDK4/6 inhibitor in metastatic hormone receptor–positive breast cancer: Insights from a tertiary care centre in India.

Aastha Goel, Ajay Gogia, Atul Batra et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13086

e13086 Background: Cyclin dependant kinase 4/6 inhibitors (CDKi), along with endocrine therapy (ET), is the first line management of metastatic hormone re...

Impact of psychological intervention on perceived distress of cancer patients: Results from a longitudinal study in India.

Niharika Bisht, Amul Kapoor, Sankalp Singh et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24062

e24062 Background: Despite the psychological impact of cancer being a well-established entity, it is often not prioritised in low to middle-income nations...

Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse.

Mark Blaine Geyer, Michaela Liedtke, Vikram Shetty et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18510

e18510 Background: While new treatment modalities, such as the bispecific T-cell engager blinatumomab (blin) and chimeric antigen receptor modified T-cell...

Phase Ib trial of C019199, an oral TME modulator targeting CSF-1R/DDRs/VEGFR2, in relapsed or refractory osteosarcoma.

Feng Ye, Tian Gao, Lu Xie et al. Jun 01, 2025 pp. 11510-11510 10.1200/jco.2025.43.16_suppl.11510

11510 Background: C019199 is an oral drug candidate that modulates the tumor micro-environment (TME) through targeting CSF...

Financial toxicity in cancer care: Experience from a tertiary care cancer center.

Mahir Khan, Elizabeth Dewey, Colleen Strzalka et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23199

e23199 Background: Financial toxicity (FT) is associated with poor quality of life (QOL) and survival and is a well-recognized, critical issue for cancer...

Real-world outcomes by DNA mismatch repair (MMR) status in patients (pts) with high-risk endometrial cancer (EC) in the adjuvant setting.

Karime Kalil Machado, Cecilia Orbegoso Aguilar, Aayushi Agarwal et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17623

e17623 Background: EC is the sixth most common cancer in women. Pts with high-risk EC are more susceptible to recurrence. Per ESMO guidelines, high-risk s...

The preliminary safety results of an observational phase II study of concurrent use of aspirin with dabrafenib and trametinib in BRAF V600 NSCLC.

Rui Han, Jianghua Li, Yong He Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20632

e20632 Background: Dabrafenib combined with trametinib (DabTram) is highly effective in treating BRAF V600-mutant non-small cell lung cancer (NSCLC). Howe...

A large centre study of pathological and clinical characteristics of signet ring and mucinous colorectal adenocarcinomas.

Adithya Sathya Narayana, Vinay C. Bellur, Advaith N. Rao et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15672

e15672 Background: Colorectal carcinoma is a rapidly growing public health problem worldwide. In India, a historically low prevalence country, rates have...

Drug-eluting beads loaded with irinotecan-transarterial chemoembolization (DEBIRI-TACE) combined with hepatic artery infusion chemotherapy and regorafenib in colorectal liver metastases refractory to second-line and above standard systemic therapy: A single-center, phase II clinical trial (DREAM).

Wenzhe Fan, Yanqing Wu, Bowen Zhu et al. Jun 01, 2025 pp. 3539-3539 10.1200/jco.2025.43.16_suppl.3539

3539 Background: For patients with colorectal liver metastasis (CRLM) who have failed in first-line or second-line systemic treatment, the prognosis is ex...

Comparison of artificial intelligence to expert physician assessments of real-world oncology cases.

Olivia Main, Matthew Struck, John L Vaughn et al. Jun 01, 2025 pp. 1564-1564 10.1200/jco.2025.43.16_suppl.1564

1564 Background: Artificial intelligence (AI) is increasingly being incorporated into the oncology field as a tool to support clinical decisions. AI tools...

Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer.

Ziming Li, Qiming Wang, Liang Han et al. Jun 01, 2025 pp. 3036-3036 10.1200/jco.2025.43.16_suppl.3036

3036 Background: 7MW3711 is a B7-H3 targeting ADC comprised of a recombinant humanized monoclonal anti-human B7-H3 antibod...

Real-world outcomes for dMMR/MSI-H colorectal cancer: Navigating rapidly evolving oncologic practices in a community hospital.

Ashish Nepal, Shreya Sudadi, Haiyun Wang Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15519

e15519 Background: The incidence of Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Colorectal Cancer (CRC) is 15% among all CRCs...

SALVOVAR: A pragmatic randomized phase III trial comparing the salvage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic ovarian cancers (GINECO-OV130b; ENGOT-ov78).

Benoît You, Nozomu Yanaihara, Gabriella Parma et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps5626

TPS5626 Background: The patients with an advanced epithelial ovarian cancer (EOC) treated with a neo-adjuvant platinum-based chemotherapy who are not amen...

Risk factors and causes of early death among patients with germ cell testis tumors (GCTs): An international collaborative study supported by the Global Society of Rare Genitourinary Tumors.

Michal Mego, Edgar Israelyan, Axel Heidenreich et al. Jun 01, 2025 pp. 5030-5030 10.1200/jco.2025.43.16_suppl.5030

5030 Background: GCTs are the most common solid tumor in young men aged 20 to 40 years and are curable in most cases. However, a small proportion of patie...

The optimized HLH inflammatory index: A novel prognostic tool for newly diagnosed patients with diffuse large B-cell lymphoma—Discovery and validation.

Adi Zoref Lorenz, Elliot Cahn, Eric Mou et al. Jun 01, 2025 pp. 7073-7073 10.1200/jco.2025.43.16_suppl.7073

7073 Background: The Optimized HLH Inflammatory (OHI) index (Zoref-Lorenz et al., Blood , 2022), based on serum soluble CD25 (sCD2...

Combined impact of patients and disease characteristics on survival outcome in early hormone receptor negative patients across SBR grades.

Tafenzi Hassan Abdelilah, Anass Baladi, Youssef AIT Takniouine et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12525

e12525 Background: Previous studies have established a correlation between Scarff-Bloom-Richardson (SBR) grades, cell proliferation, and chemo-response in...

Evaluating the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) as an adjunct to surgery for advanced ovarian cancer: A systematic review and meta-analysis of randomized controlled trials.

Abdullah Afridi, Umama Alam, Muhammad Abdullah Ali et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17579

e17579 Background: Advanced ovarian cancer remains a significant challenge in gynecologic oncology, with a 5-year survival rate of approximately 30% for p...

Immunotherapy making inroads into advanced endometrial cancer management: A single center real world experience.

Amit Rauthan, Poonam Patil, Nitin Yashas Murthy et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17635

e17635 Background: Chemotherapy with carboplatin and paclitaxel was the standard treatment for advanced endometrial cancer (EC) for many years. In recent...

High-dose furmonertinib combined with bevacizumab and pemetrexed in non-small cell lung cancer patients with <i> <i>EGFR</i> </i> mutations and leptomeningeal metastasis: A prospective real-world study.

Qi Zhao, Haiyang Chen, Lili Wang et al. Jun 01, 2025 pp. 8609-8609 10.1200/jco.2025.43.16_suppl.8609

8609 Background: Leptomeningeal metastasis (LM) in lung cancer is always associated with poor prognosis. Our previous study has demonstrated that high-dos...

Hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer: An updated systematic review and meta-analysis.

Yemesrach Mekonen, Gabriel Bonetti Barbuto, Sanjay Eda et al. Jun 01, 2025 pp. 5584-5584 10.1200/jco.2025.43.16_suppl.5584

5584 Background: Ovarian cancer is the leading cause of mortality among gynecological malignancies in women. Disease recurrence remains a formidable chall...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page